Angiogenic biomarkers in children with congenital heart disease: possible implications.
BACKGROUND
Vascular endothelial growth factor (VEGF), platelet derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) and leptin are known as potent angiogenic factors The objective of the study was to evaluate these angiogenic factors VEGF, PD-ECGF/TP and leptin in children with congenital heart disease (CHD) and the factors that lead to angiogenesis in such cases.


METHODS
Sixty CHD children were studied and divided into two groups (n=30); cyanotic-CHD (C-CHD) and acyanotic-CHD (A-CHD). Twenty five healthy children were included as controls.


RESULTS
Significantly higher serum levels of VEGF, PD-ECGF/TP activity and leptin were detected in patients with CHD, particularly in patients with C-CHD. CHD patients with SpO2<90%, pulmonary hypertension (PH), severe pulmonary stenosis (PS), detectable collaterals, cardiomegaly and/or heart failure showed significantly higher levels of these factors than those with higher SpO2 or those without these findings.


CONCLUSIONS
Hypoxia, PH and PS are important factors that lead to harmful angiogenesis. However, angiogenesis could be essential in some cases of CHD as coarctation of aorta to enhance renal perfusion. This may provide new ways for therapeutic strategies aiming at reducing or promoting angiogenesis in CHD to improve patient's outcome.
El-Melegy
Nagla T
NT
Medical Biochemistry Department, Faculty of Medicine, Assiut University, Assiut, (71515), Egypt. elmelegynagla@yahoo.com
Mohamed
Nagwa A
NA
D015415:Biomarkers / Q000097:blood*; D002675:Child, Preschool; D018450:Disease Progression; D004452:Echocardiography; D005260:Female; D006330:Heart Defects, Congenital / Q000097:blood / Q000150:complications* / Q000000981:diagnostic imaging; D006801:Humans; D020738:Leptin / Q000097:blood; D008297:Male; D009389:Neovascularization, Pathologic / Q000097:blood* / Q000209:etiology; D011379:Prognosis; D013053:Spectrophotometry; D013939:Thymidine Phosphorylase / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D015415:Biomarkers; D020738:Leptin; D042461:Vascular Endothelial Growth Factor A; D013939:Thymidine Phosphorylase
Cancer Res. 1997 Feb 15;57(4):570-2
9044826
Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L222-31
12665467
Br J Pharmacol. 2003 May;139(2):219-31
12770927
Cancer Res. 2000 Nov 15;60(22):6298-302
11103787
J Clin Invest. 2007 Sep;117(9):2362-8
17786229
Pharmacol Rev. 2000 Jun;52(2):237-68
10835101
Basic Res Cardiol. 2007 May;102(3):224-32
17268888
N Engl J Med. 1996 Feb 1;334(5):292-5
8532024
Int J Cardiol. 2003 Nov;92(1):93-7
14602223
J Biol Chem. 1999 Aug 27;274(35):25130-5
10455194
Heart Dis. 2000 Sep-Oct;2(5):362-8
11728283
Methods Enzymol. 1978;51:432-7
308598
Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H408-15
15374822
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6390-5
11344271
Exp Physiol. 2008 Mar;93(3):434-42
17993509
J Thorac Cardiovasc Surg. 2000 Mar;119(3):534-9
10694614
Hypertension. 2006 May;47(5):887-93
16567591
Biochem J. 2006 Jan 1;393(Pt 1):7-20
16336196
Eur Heart J. 2003 Apr;24(7):586-603
12657217
Circ J. 2005 Sep;69(9):1089-93
16127192
Pathol Oncol Res. 2001;7(2):85-94
11458270
J Clin Invest. 2007 Nov;117(11):3188-97
17975666
Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2334-41
15964923
Ann Thorac Surg. 2004 Sep;78(3):942-6; discussion 946-7
15337024
Ann Thorac Surg. 2003 May;75(5):1523-6
12735573
Circulation. 1999 Jan 5-12;99(1):111-20
9884387
Chest. 1998 Sep;114(3 Suppl):237S-241S
9741575
J Biol Chem. 2002 Sep 13;277(37):34601-9
12084725
Pediatr Cardiol. 2003 Mar-Apr;24(2):127-32
12360391
Physiol Res. 2000;49(5):485-92
11191354
Diabetes. 2004 Sep;53(9):2443-8
15331557